메뉴 건너뛰기




Volumn 104, Issue 12, 2013, Pages 1656-1661

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

EID: 84889592108     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12282     Document Type: Article
Times cited : (91)

References (35)
  • 1
    • 0029021935 scopus 로고
    • Incidence of second cancers in patients treated for Hodgkin's disease
    • Boivin JF, Hutchison GB, Zauber AG et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 732-41.
    • (1995) J Natl Cancer Inst , vol.87 , pp. 732-741
    • Boivin, J.F.1    Hutchison, G.B.2    Zauber, A.G.3
  • 2
    • 0033952110 scopus 로고    scopus 로고
    • Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
    • van Leeuwen FE, Klokman WJ, Veer MB et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487-97.
    • (2000) J Clin Oncol , vol.18 , pp. 487-497
    • van Leeuwen, F.E.1    Klokman, W.J.2    Veer, M.B.3
  • 3
    • 0037089650 scopus 로고    scopus 로고
    • Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger
    • Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002; 20: 2101-8.
    • (2002) J Clin Oncol , vol.20 , pp. 2101-2108
    • Ng, A.K.1    Bernardo, M.P.2    Weller, E.3
  • 4
    • 33845354279 scopus 로고    scopus 로고
    • Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
    • Franklin J, Pluetschow A, Paus M et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006; 17: 1749-60.
    • (2006) Ann Oncol , vol.17 , pp. 1749-1760
    • Franklin, J.1    Pluetschow, A.2    Paus, M.3
  • 5
    • 33745982566 scopus 로고    scopus 로고
    • Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials
    • Noordijk EM, Carde P, Dupouy N et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35.
    • (2006) J Clin Oncol , vol.24 , pp. 3128-3135
    • Noordijk, E.M.1    Carde, P.2    Dupouy, N.3
  • 6
    • 34548186696 scopus 로고    scopus 로고
    • Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial
    • Engert A, Franklin J, Eich HT et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502.
    • (2007) J Clin Oncol , vol.25 , pp. 3495-3502
    • Engert, A.1    Franklin, J.2    Eich, H.T.3
  • 7
    • 9444292843 scopus 로고    scopus 로고
    • Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    • Straus DJ, Portlock CS, Qin J et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-9.
    • (2004) Blood , vol.104 , pp. 3483-3489
    • Straus, D.J.1    Portlock, C.S.2    Qin, J.3
  • 8
    • 10944270230 scopus 로고    scopus 로고
    • Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study
    • Rueda Domínguez A, Márquez A, Gumá J et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004; 15: 1798-804.
    • (2004) Ann Oncol , vol.15 , pp. 1798-1804
    • Rueda Domínguez, A.1    Márquez, A.2    Gumá, J.3
  • 9
    • 33645998113 scopus 로고    scopus 로고
    • The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease
    • Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-81.
    • (2006) Haematologica , vol.91 , pp. 475-481
    • Gallamini, A.1    Rigacci, L.2    Merli, F.3
  • 10
    • 30144432586 scopus 로고    scopus 로고
    • FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
    • Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
    • (2006) Blood , vol.107 , pp. 52-59
    • Hutchings, M.1    Loft, A.2    Hansen, M.3
  • 11
    • 34548486030 scopus 로고    scopus 로고
    • Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study
    • Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-52.
    • (2007) J Clin Oncol , vol.25 , pp. 3746-3752
    • Gallamini, A.1    Hutchings, M.2    Rigacci, L.3
  • 12
    • 0036124658 scopus 로고    scopus 로고
    • Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
    • Wirth A, Seymour JF, Hicks RJ et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002; 112: 262-8.
    • (2002) Am J Med , vol.112 , pp. 262-268
    • Wirth, A.1    Seymour, J.F.2    Hicks, R.J.3
  • 13
    • 9444279658 scopus 로고    scopus 로고
    • Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
    • Munker R, Glass J, Griffeth LK et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004; 15: 1699-704.
    • (2004) Ann Oncol , vol.15 , pp. 1699-1704
    • Munker, R.1    Glass, J.2    Griffeth, L.K.3
  • 14
    • 0036938607 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease
    • Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-5.
    • (2002) Ann Hematol , vol.81 , pp. 20-25
    • Weihrauch, M.R.1    Re, D.2    Bischoff, S.3
  • 15
    • 25444437438 scopus 로고    scopus 로고
    • Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    • Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-8.
    • (2005) Ann Oncol , vol.16 , pp. 1160-1168
    • Hutchings, M.1    Mikhaeel, N.G.2    Fields, P.A.3
  • 16
    • 84861469135 scopus 로고    scopus 로고
    • Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement
    • Song MK, Chung JS, Shin HJ et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91: 697-703.
    • (2012) Ann Hematol , vol.91 , pp. 697-703
    • Song, M.K.1    Chung, J.S.2    Shin, H.J.3
  • 17
    • 84859741903 scopus 로고    scopus 로고
    • Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma
    • Song MK, Chung JS, Shin HJ et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci 2012; 103: 477-82.
    • (2012) Cancer Sci , vol.103 , pp. 477-482
    • Song, M.K.1    Chung, J.S.2    Shin, H.J.3
  • 18
    • 84870907232 scopus 로고    scopus 로고
    • Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma
    • Song MK, Chung JS, Shin HJ et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma. Leuk Res 2013; 37: 58-63.
    • (2013) Leuk Res , vol.37 , pp. 58-63
    • Song, M.K.1    Chung, J.S.2    Shin, H.J.3
  • 19
    • 84887588744 scopus 로고    scopus 로고
    • Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP
    • Oh MY, Chung JS, Song MK et al. Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 2013; 97: 397-402.
    • (2013) Int J Hematol , vol.97 , pp. 397-402
    • Oh, M.Y.1    Chung, J.S.2    Song, M.K.3
  • 20
    • 0141939066 scopus 로고    scopus 로고
    • Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma
    • Engert A, Schiller P, Josting A et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma. J Clin Oncol 2003; 19: 3601-8.
    • (2003) J Clin Oncol , vol.19 , pp. 3601-3608
    • Engert, A.1    Schiller, P.2    Josting, A.3
  • 21
    • 0024422603 scopus 로고
    • Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting
    • Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
    • (1989) J Clin Oncol , vol.7 , pp. 1630-1636
    • Lister, T.A.1    Crowther, D.2    Sutcliffe, S.B.3
  • 23
    • 72949107608 scopus 로고    scopus 로고
    • FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    • Boellaard R, O'Doherty MJ, Weber WA et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
    • (2010) Eur J Nucl Med Mol Imaging , vol.37 , pp. 181-200
    • Boellaard, R.1    O'Doherty, M.J.2    Weber, W.A.3
  • 24
    • 21044445135 scopus 로고    scopus 로고
    • The EORTC strategy in the treatment of Hodgkin's lymphoma
    • Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; 66: 135-40.
    • (2005) Eur J Haematol Suppl , vol.66 , pp. 135-140
    • Eghbali, H.1    Raemaekers, J.2    Carde, P.3
  • 25
    • 84861813756 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines
    • Hoppe RT, Advani RH, Ai WZ et al. National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 589-97.
    • (2012) J Natl Compr Canc Netw , vol.10 , pp. 589-597
    • Hoppe, R.T.1    Advani, R.H.2    Ai, W.Z.3
  • 26
    • 0037905550 scopus 로고    scopus 로고
    • Hodgkin's disease-clinical trials and travails
    • DeVita VT Jr. Hodgkin's disease-clinical trials and travails. N Engl J Med 2003; 348: 2375-6.
    • (2003) N Engl J Med , vol.348 , pp. 2375-2376
    • DeVita Jr., V.T.1
  • 27
    • 0042308850 scopus 로고    scopus 로고
    • Radiation therapy in the treatment of Hodgkin's disease-do you see what I see?
    • Longo DL. Radiation therapy in the treatment of Hodgkin's disease-do you see what I see? J Natl Cancer Inst 2003; 95: 928-9.
    • (2003) J Natl Cancer Inst , vol.95 , pp. 928-929
    • Longo, D.L.1
  • 28
    • 26944442771 scopus 로고    scopus 로고
    • Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory?
    • Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005; 97: 1394-5.
    • (2005) J Natl Cancer Inst , vol.97 , pp. 1394-1395
    • Longo, D.L.1
  • 29
    • 23044438039 scopus 로고    scopus 로고
    • Chemotherapy alone for early Hodgkin's lymphoma: an emerging option
    • Canellos GP. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol 2005; 23: 4574-6.
    • (2005) J Clin Oncol , vol.23 , pp. 4574-4576
    • Canellos, G.P.1
  • 30
    • 0035281969 scopus 로고    scopus 로고
    • Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance
    • Gobbi PG, Ghirardelli ML, Solcia M et al. Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. J Clin Oncol 2001; 19: 1388-94.
    • (2001) J Clin Oncol , vol.19 , pp. 1388-1394
    • Gobbi, P.G.1    Ghirardelli, M.L.2    Solcia, M.3
  • 31
    • 4744376311 scopus 로고    scopus 로고
    • The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
    • Gobbi PG, Broglia C, Di Giulio G et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer 2004; 101: 1824-34.
    • (2004) Cancer , vol.101 , pp. 1824-1834
    • Gobbi, P.G.1    Broglia, C.2    Di Giulio, G.3
  • 32
    • 0033566341 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
    • Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-33.
    • (1999) Blood , vol.94 , pp. 429-433
    • Jerusalem, G.1    Beguin, Y.2    Fassotte, M.F.3
  • 33
    • 0032587391 scopus 로고    scopus 로고
    • Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
    • Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
    • (1999) Nucl Med Commun , vol.20 , pp. 13-20
    • Jerusalem, G.1    Warland, V.2    Najjar, F.3
  • 34
    • 0031869324 scopus 로고    scopus 로고
    • Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
    • Stumpe KD, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
    • (1998) Eur J Nucl Med , vol.25 , pp. 721-728
    • Stumpe, K.D.1    Urbinelli, M.2    Steinert, H.C.3
  • 35
    • 34748865484 scopus 로고    scopus 로고
    • The International Harmonization Project for response criteria in lymphoma clinical trials
    • Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007; 21: 841-54.
    • (2007) Hematol Oncol Clin North Am , vol.21 , pp. 841-854
    • Cheson, B.D.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.